Add this topic to your myFT Digest for news straight to your inbox
The global health community — together with pharmaceutical companies — must prove they take maternal rights seriously
‘Molecular factories’ boost field of synthetic biology, raising hopes of developing drugs and other products
Expanded genetic profiling could lead to breakthroughs in diagnosis and therapy for common tumours, landmark global study finds
H5N1 cases in South Georgia increase concerns about virus’s ability to adapt and infect mammals and humans more easily
Study harnesses millennia-old human DNA to plot ‘genetic divide’ on origin and spread of health risks
Medical experts call for curbs on agricultural fungicides
Oxford university spinout working on polygenic risk scores to help predict disease
Winter surge in people catching flu, Covid-19 or RSV risks overwhelming hospitals
A trial of $3 payments for getting a Covid jab in rural Ghana offers a game-changing way to meet public health goals
Potential remedy targets leading antibiotic-resistant pathogen that causes life-threatening infections in patients
Millions of Paxlovid pills have gone unused as tight controls restrict access
Focused adoption will follow this year’s fun experimentation
Americans’ interest in vaccinations has flagged despite efforts to boost uptake of latest jab
Debates about crucial topics such as AI and net zero currently exclude large swaths of the population
Research into ‘colonisation resistance’ boosts efforts to harness microbes to improve general health
Belfast-based CV6 Therapeutics announced MHRA approval for trials of novel therapy pill
Anglo-Swedish pharma group agrees to buy Seattle-based biotech Icosavax
Organoid helps system recognise speech and solve maths problems showing potential of neuromorphic technology
‘Treasure trove’ will be used to develop drugs and treatments for wide range of diseases and is culmination of 20 years of work
Non-profit offers $101mn for discoveries that will restore muscle, brain and immune functions
No evidence to support ‘popular ideas that certain groups are more at risk’, according to researchers
Innovative models can drive funding for research on neglected, less survivable diseases
Bill Anderson says group is generating a series of promising new drugs after R&D strategy change
Health body’s concern reflects heightened vigilance over signs of disease outbreaks since Covid pandemic
German group says prospective blockbuster asundexian failed to demonstrate efficacy
International Edition